Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stimolazione Meccanica Intra-Nasale (INMEST) come Potenziale Trattamento Preventivo per l'Emicrania (A-MI-01)

2 novembre 2026 aggiornato da: Abilion Medical Systems AB

Stimolazione Meccanica Intra-Nasale (INMEST) come Trattamento Preventivo Potenziale per l'Emicrania - Uno Studio Prospettico, Randomizzato, in Aperto, a Inizio Ritardato per Valutare la Sicurezza e le Prestazioni del Sistema Walther

This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical stimulation (INMEST), as a preventative treatment for migraine. A total of 110 adults (18-65 years) with a history of migraine will be randomized 1:1 into two groups: Group A (early treatment) and Group B (delayed treatment). The study includes baseline assessments, in-clinic device training, and home-based self-administered treatments every second day for six weeks. The primary outcome is the change in monthly migraine days during the primary treatment comparison period. Secondary outcomes include headache days, migraine intensity, duration, rescue medication use, patient-reported outcomes, device compliance, and safety. The study will be conducted at one site in Sweden.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

110

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Stockholm, Svezia, 11327
        • INMEST-mottagningen Odenplan

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age 18-65 years at the time of screening.

  2. The study subject must have a clinical diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-3), indicated by medical record shown by the subject.

  3. Onset of migraine headache occurred before age 50.

  4. History of migraines for at least 1 year before screening.

  5. The study subject reports at least 8 monthly migraine days during the screening period.

  6. If subject is on a prophylactic migraine medication regimen:

    1. Reports stable medication regimen during the three months prior to screening.
    2. Able and willing to maintain medication regimen (no change in type, frequency or dose) from screening to end of follow-up.
  7. The study subject reports having understood and have signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.

  8. Women of childbearing potential must agree to use a reliable, medically approved form of contraception during the study participation until end of study.

  9. Anticipated compliance with prescribed treatment and follow-up.

Exclusion Criteria:

  1. Subject unable to distinguish between migraine headaches and other headache types.
  2. Recently (12 months prior screening) undergone nasal or sinus surgery.
  3. Any severe diseases for which, in the opinion of the Investigator, participation would not be in the best interest of the subject or that can interfere with the performance, evaluation, and outcome of the clinical evaluation.
  4. Previous (within 30 days prior to screening) and concurrent treatment with another investigational drug/s or device/s.
  5. Subject is pregnant or lactating or planning to get pregnant during the duration of the study.
  6. The study subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation.
  7. The study subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Group A - Early Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), then receive active treatment with the Walther System every second day for 6 weeks (weeks 5-10). The first treatment is performed under supervision at the clinic, and subsequent treatments are self-administered at home. Post-treatment assessments occur during weeks 11-14.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Altri nomi:
  • Walther System
Comparatore attivo: Group B - Delayed Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), followed by a 6-week no-treatment reference period (weeks 5-10). Active treatment with the Walther System is then administered every second day for 6 weeks (weeks 11-16), starting with an initial supervised treatment at the clinic. Post-treatment assessments occur during weeks 17-20.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Altri nomi:
  • Walther System

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Monthly Migraine Days
Lasso di tempo: Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Between-group comparison of the difference in mean change in monthly migraine days from the baseline assessment period (weeks 1-4) to Group A) Treatment performance period (weeks 7-10) and Group B) No treatment reference period (weeks 7-10).

Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean change in monthly headache days
Lasso di tempo: Weeks 7-10

Between-group comparison of the difference in mean change in monthly headache days from baseline.

Weeks 7-10
Mean change in migraine intensity
Lasso di tempo: Weeks 7-10

Between-group comparison of the difference in mean change in migraine intensity from baseline.

Weeks 7-10
Mean change in duration of migraine attacks
Lasso di tempo: Weeks 7-10

Between-group comparison of the difference in mean change in migraine attack duration (hours) from baseline.

Weeks 7-10
Proportion of attacks requiring rescue medication
Lasso di tempo: Weeks 7-10

Between-group comparison of the proportion of migraine attacks requiring rescue medication.

Weeks 7-10
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Lasso di tempo: Weeks 7-10

Between-group comparison of the proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days.

Weeks 7-10
Mean change in PROMIS-PI SF-6b
Lasso di tempo: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PROMIS-PI SF-6b scores. The raw scores are converted to standardized T-scores (range 0-100; mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Weeks 7-10
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Lasso di tempo: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in MSQ scores. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Weeks 7-10
Mean change in Patient Global Impression of Severity (PGI-S)
Lasso di tempo: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PGI-S scores. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Weeks 7-10
Mean change in monthly migraine days
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity within each group. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours) within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores within each group. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores within each group. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores within each group. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly migraine days
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity, pooled across both groups. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity."

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours), pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores, pooled across both groups. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores, pooled across both groups. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
Lasso di tempo: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores, pooled across both groups. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of prescribed treatments completed
Lasso di tempo: Throughout the 6-week treatment period

Compliance based on device usage logs or participant-reported treatment diaries.

Throughout the 6-week treatment period
Adverse Events / Serious Adverse Events / Device Effects
Lasso di tempo: Through study completion (14 or 20 weeks, depending on treatment group)

Number of treatment-related AEs, SAEs, ADEs, SADEs, and Unanticipated SADEs for the Walther System.

Through study completion (14 or 20 weeks, depending on treatment group)
Device Deficiencies
Lasso di tempo: Throughout the 6-week treatment period

Number of device deficiencies for the Walther System.

Throughout the 6-week treatment period

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Device usability and user experience (combined questionnaires)
Lasso di tempo: Throughout the 6-week treatment period

User-reported usability, ease of use, handling, and overall experience of the device during home use, assessed using two Device Usability Questionnaires. Questions include multiple 3- or 5-point scales, 0-10 scales, and yes/no responses. Higher scores indicate better usability or greater interest where applicable.

Throughout the 6-week treatment period
Symptom trends (Symptom Questionnaire)
Lasso di tempo: Throughout the 6-week treatment period

Changes in symptoms potentially related to autonomic nervous system function, assessed using the Symptom Questionnaire at Visits 1-5. The questionnaire includes multiple items with 0-6 and 0-3 ordinal scales, yes/no responses, and other response formats. Higher scores indicate more severe symptoms."

Throughout the 6-week treatment period

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Jan-Erik Juto, PhD, MD

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

21 ottobre 2025

Completamento primario (Stimato)

1 novembre 2026

Completamento dello studio (Stimato)

1 novembre 2026

Date di iscrizione allo studio

Primo inviato

18 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

10 dicembre 2025

Primo Inserito (Effettivo)

12 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • A-MI-01
  • CIV-25-05-052936 (Identificatore di registro: Swedish Clinical Trials Registry)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .